Table 1.
Baseline demographic and clinical characteristics for NA-ACCORD (N = 717) and COMPLETE cohorts (N = 450)
| Characteristic | PWoH with TCL and NK/TCL (n = 450 | PWH with TCL and NK/TCL (n = 52) | PWH with BL (n = 101) | PWH with PCNSL (n = 64) | PWH with DLBCL (n = 500) | P * | P † |
|---|---|---|---|---|---|---|---|
| Age at diagnosis of lymphoma (y), median (IQR) | 60 (48-70) | 49 (43-55) | 47 (39-51) | 41 (37-49) | 47 (40-55) | <.001 | .12 |
| Biological sex, no. (%) | |||||||
| Male | 283 (63) | 50 (96) | 94 (93) | 58 (91) | 437 (87) | <.001 | .11 |
| Race, no. (%) | |||||||
| White | 339/438 (77) | 30/47 (64) | 58/94 (62) | 21/58 (37) | 255/461 (55) | .006‡ | .51‡ |
| Black | 67/438 (15) | 16/47 (34) | 31/94 (33) | 34/58 (59) | 189/461 (41) | ||
| Other | 32/438 (7) | 1/47 (2) | 5/94 (5) | 3/58 (5) | 17/461 (4) | ||
| Comorbid conditions, no. (%) | |||||||
| Chronic kidney disease§ | 10 (2.2) | 10 (19) | 7 (7) | 2 (3) | 62 (12) | <.001‡ | .07‡ |
| Coinfections, no. (%) ǁ | |||||||
| HBV | 4 (0.9) | 7 (13) | 7 (7) | 7 (11) | 54/494 (11) | <.001‡ | .63 |
| HCV | 5 (1.1) | 10 (19) | 23 (23) | 11 (17) | 100 (20) | <.001‡ | >.99 |
| No of cases per calendar period, no. (%) | |||||||
| 1996-1999 2000-2009 2010-2016 | 450 (100) | 10 (19) 29 (56) 13 (25) | 13 (13) 54 (53) 34 (34) | 27 (42) 31 (48) 6 (9) | 67 (13) 292 (58) 141 (28) | .82 | |
| Alive at study exit, no. (%) | 233 (52) | 18 (35) | 53 (52) | 11 (17) | 200 (40) | .05 | .57 |
| Histologic subtypes | |||||||
| ATLL | 13 (3) | 1 (2) | >.99‡ | ||||
| AITL | 73 (16) | 3 (6) | .07 | ||||
| ALCL | 79 (18) | 26 (50) | <.001 | ||||
| CTCL | 26 (6) | 4 (8) | .54‡ | ||||
| PTCL-NOS | 143 (32) | 12 (23) | .26 | ||||
| NK/TCL | 46 (10) | 3 (6) | .44 | ||||
| T-LGL | 0 | 3 (6) | |||||
| Age at NA-ACCORD enrollment (y), median (IQR) | 44 (41-50) | 43 (35-47) | 39 (34-45) | 43 (36-50) | .08 | ||
| Time to diagnosis of lymphoma from time of NA-ACCORD enrollment (y), median (IQR) | 2.3 (0.3-5.9) | 2.8 (1.0-6.7) | 1.9 (0.6-4.3) | 3.0 (0.7-7.2) | .21 | ||
IQR, interquartile range.
P values for the comparison between patients with TCL and NK/TCL with vs without HIV infection were calculated using t tests and χ2 tests for continuous and categorical variables, respectively.
P values for the comparison between patients with TCL and NK/TCL vs with B-cell NHL (Burkitt’s, PCNSL, DLBCL combined) were calculated using t tests, Wilcoxon rank sum tests, and χ2 tests for normally distributed continuous, non-normally distributed continuous, and categorical variables, respectively.
P values based on Fisher’s exact test because of some small cell counts.
Patient with CKD were defined as those who ever had an eGFR consistently <60 mL/min per 1.73 m2 for at least 3 months.
HBV, hepatitis B virus, as determined by detection of surface antigen, e antigen, or DNA quantification; HCV, hepatitis C virus as determined by detection of antibody, RNA quantification, or genotype.